Bli medlem
Bli medlem

Du är här


Swedish Orphan Biovitrum AB: Sobi™ publishes 2020 Annual and Sustainability Report

Swedish Orphan Biovitrum AB (publ) ( (Sobi™) has released the company's 2020 Annual and Sustainability Report. The integrated report summarises our business and strategy, financial performance and work on sustainability.

"In 2020, we continued to take major steps in the transformation of the company and expanded beyond our traditional stronghold in haemophilia. We achieved solid growth during the year, and broadened the foundation of the company to align with our ambition of becoming a global leader in rare disease," said Guido Oelkers, CEO and President.

Sobi's 2020 Annual and Sustainability Report is available on (

About Sobi™

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and Asia. In 2020, Sobi's revenues amounted to SEK 15.3 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at

For more information, please contact

Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599

Maria Kruse, Corporate Communication & Investor Relations
+ 46 767 248 830

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.